Asterix Foods raises US$4.2M to redefine precision fermentation with plant cell bioreactor technology

ISRAEL – Asterix Foods, a food-tech startup, has unveiled its operations with a US$4.2 million Seed funding round led by CPT Capital, alongside ReGen Ventures, SOSV, Grok Ventures, and the Israeli Innovation Authority. 

The company is pioneering an alternative to precision fermentation using a plant cell culture platform that drastically reduces costs while maintaining high functional performance in producing animal-free, bioactive proteins.

Precision fermentation has long been a cornerstone of protein innovation, allowing microbes to produce valuable compounds through engineered bioreactors. 

However, scaling this process remains prohibitively expensive, with traditional facilities demanding between US$125 million and US$500 million in capital expenditure. 

Asterix Foods’ proprietary approach replaces microbial engineering with plant cell suspension cultures grown inside Massively Parallel Modular Bioreactors (MPMB), reducing facility costs by over 95% and slashing production timelines from years to months.

According to CEO Dan Even, who holds a Ph.D. in Plant Molecular Biology and Genetic Engineering from the Weizmann Institute of Science, the company’s technology delivers a combination of cost-efficiency, flexibility, and sustainability. 

“Our system shows how future protein production facilities can be deployed quickly and at dramatically lower cost, while maintaining high bioactivity,” he noted.

Plant cells provide several advantages over microbial systems. Being multicellular, they have evolved complex protein-processing machinery capable of producing glycoproteins and other molecules that microbes cannot synthesize efficiently. 

They are also less susceptible to contamination, enabling production in simpler, non-sterile environments and eliminating the need for expensive cleanrooms, steam sterilization, or stainless-steel infrastructure.

Asterix currently operates a pilot facility in central Tel Aviv to demonstrate the scalability of its technology. 

The modular system supports geographically flexible deployment, allowing production on non-arable land, near manufacturing hubs, or within existing food facilities. 

Each compact unit can run dual production lines, support multiple protein types, and operate continuously year-round without extensive downtime for cleaning or maintenance.

Investors view Asterix’s model as a critical leap in sustainable protein manufacturing.

“Their capex-light and modular system gives customers the flexibility to locate production exactly where it’s needed,” said CPT Capital’s Harry Kalms. 

Po Bronson of SOSV added that plant cell suspension technology, already used in pharmaceuticals and pigments, now opens the door to producing alternative proteins with unmatched cost-efficiency.

Founded in 2022, Asterix Foods plans to use its new funding to expand its Tel Aviv pilot facility and deliver protein samples to early partners, advancing its mission to make sustainable, functional proteins widely accessible.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.